Nabriva Therapeutics plc (NASDAQ: NBRV) today announced that it has completed enrollment in its second lefamulin evaluation against pneumonia (LEAP ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE